Bionano Genomics, Inc. (NASDAQ:BNGO) Short Interest Update

Bionano Genomics, Inc. (NASDAQ:BNGO) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 1,370,000 shares, an increase of 93.9% from the September 15th total of 706,400 shares. Approximately 17.0% of the company’s shares are sold short. Based on an average daily trading volume, of 601,900 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily trading volume, of 601,900 shares, the days-to-cover ratio is currently 2.3 days. Approximately 17.0% of the company’s shares are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bionano Genomics stock. Everstar Asset Management LLC acquired a new position in Bionano Genomics, Inc. (NASDAQ:BNGO) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 44,984 shares of the company’s stock, valued at approximately $126,000. Everstar Asset Management LLC owned 1.45% of Bionano Genomics as of its most recent SEC filing. 11.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BNGO has been the subject of several recent analyst reports. Wall Street Zen raised shares of Bionano Genomics from a “sell” rating to a “hold” rating in a research report on Monday, August 25th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective (up from $10.00) on shares of Bionano Genomics in a research note on Monday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bionano Genomics presently has a consensus rating of “Hold” and a consensus target price of $7.50.

Bionano Genomics Price Performance

Shares of Bionano Genomics stock opened at $1.92 on Thursday. The company has a market cap of $7.95 million, a PE ratio of -0.01 and a beta of 2.19. The business has a 50 day moving average of $2.76 and a 200 day moving average of $3.29. Bionano Genomics has a 52 week low of $1.50 and a 52 week high of $22.80. The company has a quick ratio of 1.41, a current ratio of 1.76 and a debt-to-equity ratio of 0.08.

Bionano Genomics (NASDAQ:BNGO) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($1.99) earnings per share for the quarter, topping the consensus estimate of ($2.69) by $0.70. Bionano Genomics had a negative return on equity of 129.41% and a negative net margin of 271.02%.The company had revenue of $6.73 million for the quarter, compared to analysts’ expectations of $6.90 million. Bionano Genomics has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.